Celltech and Biogen announce world-wide collaboration, to develop and commercialise Phase III Crohn´s Disease product
Companies Also to Explore CDP 571 in Psoriasis Patients
25-Apr-2002 -
Slough, UK and Cambridge, MA - April 24, 2002 - Celltech Group Plc and Biogen, Inc. today announced a collaboration for the research, development, manufacturing and commercialization of CDP 571, Celltech’s humanized anti-TNF? antibody product, which is in Phase III development as a treatment for ...
antibody fragments
Italy
orphan drugs
+1